Hairy cell leukemia is a rare hematological malignancy that affects the blood, bone marrow, spleen, and other organs. First described in the late 1950s, the disease is characterized by the overgrowth of abnormal white blood cells, which crowds out the production of normal blood cells and leaves patients vulnerable to infection, anemia, and bleeding complications. The cancer takes its name from a striking microscopic feature: the malignant cells carry short, thin, hair-like projections on their surface, giving them an unmistakable appearance under the microscope. Approximately 1,200 Americans receive a diagnosis each year, and for reasons that remain unknown, men are affected four times more often than women.

One of the most important conceptual advances in recent years has been the recognition that hairy cell leukemia is not a single disease but two distinct entities: classic hairy cell leukemia and hairy cell leukemia variant. Classic disease is by far the more common form, accounting for up to 90 percent of cases. Thanks to current treatments, most patients with classic hairy cell leukemia remain in remission for five to 15 years or more, a remarkable achievement for a blood cancer that once carried a grim prognosis. Variant disease, by contrast, is far more aggressive. Roughly 10 to 15 percent of patients have the variant form, which tends to respond less well to therapy, relapses more quickly, and carries a poor survival rate. Patients with classic disease who relapse also face a much worse outlook. Closing this gap between the success achieved in classic disease and the unmet needs of variant and relapsed patients is the central focus of the latest round of grants.

The six new awards zero in on a range of aspects of the disease, supporting patients from initial diagnosis and throughout their treatment. At The Ohio State University, Christopher Oakes, Ph.D., is working to advance understanding and classification of hairy cell leukemia in individual patients. Precise classification is the essential first step in ensuring that each patient receives the right treatment, particularly in a rare cancer where expertise is concentrated at a limited number of centers. At Dana-Farber Cancer Institute in Boston, Gregory Abel, M.D., M.P.H., is examining quality of life, decision-making, and outcomes for patients, acknowledging that survival is only one measure of success in a chronic disease that can require repeated courses of therapy.

At Stanford University in California, Gerlinde Wernig, M.D., is focused on finding new methods to improve disease prognosis, including understanding the factors that lead to relapse and to the development of variant disease. Her work addresses one of the deepest questions in the field: why some patients respond beautifully to treatment while others progress to more aggressive forms. At Case Western Reserve University in Cleveland, Reshmi Parameswaran, Ph.D., is examining how hairy cell leukemia becomes resistant to treatment and developing new therapeutic strategies for the variant form. Drug resistance is a central mechanism behind relapse, and unraveling it at the molecular level could open the door to treatments that overcome or prevent it.

Two of the grants support clinical trials testing combination therapies in Europe. Enrico Tiacci, M.D., at the University of Perugia in Italy, will be testing an all-oral combination treatment for patients whose hairy cell leukemia has relapsed. Tiacci’s involvement in this partnership is not new: his groundbreaking earlier work, also supported by research funds from this collaboration, established the drug vemurafenib as an alternative to the chemotherapy-based standard of care. Vemurafenib targets the BRAF mutation that drives the vast majority of classic hairy cell leukemia cases, and its success transformed the treatment landscape for relapsed patients who had exhausted conventional options.

Across the Atlantic, Francesco Forconi, M.D., Ph.D., at the University of Southampton in the United Kingdom, is testing whether a combination of two drugs that inhibit different proteins involved in hairy cell leukemia can produce deep, long-lasting remissions. The ambition behind his trial is a fixed-duration treatment paradigm: patients would stop therapy after a defined period and remain in remission, rather than having to take treatment indefinitely. For a rare cancer where patients may live for decades with their disease, the difference between lifelong therapy and a finite course with durable remission is profound, both medically and in terms of quality of life.

The scale and coordination of the HCL2030 program reflect a deliberate strategy for a rare disease. Because hairy cell leukemia affects relatively few patients, no single institution sees enough cases to drive major advances alone. Lore Gruenbaum, Ph.D., chief scientific officer at Blood Cancer United, emphasized this point, noting that medical research is not a solo sport. Even though researchers are working at different locations across two continents, she said, they are all very much on the same team, and that cooperation is particularly important for rare diseases such as hairy cell leukemia. It takes cooperation, time, and money, she added, to find the advances that will make a real difference for patients.

Anna Lambertson, executive director of the Hairy Cell Leukemia Foundation, framed the grants as the direct result of patient and family commitment to the cause. For patients with classic hairy cell leukemia, she noted, the field has achieved years and often decades of remission. Patients with variant disease, and those who relapse, deserve treatments that work just as well, she said, describing the grants as the way to close that gap. The Hairy Cell Leukemia Foundation, founded in 1984, is the only United States nonprofit solely focused on the disease. Founded and governed by patients, it funds innovative research, advances education, and provides peer support worldwide, and its patient-led mission has helped drive major treatment advances over four decades.

Blood Cancer United, the largest global nonprofit focused on blood cancer patient support, research, and advocacy, has served people affected by more than 100 types of blood cancer since its founding in 1949. The organization funds innovative research, offers free resources and personalized support, and advocates for more accessible and affordable healthcare for all patients. Together, the two organizations have turned the HCL2030 program into a coordinated engine for progress in a cancer that receives little attention relative to its impact on those it affects. With nearly $7 million in new investment now flowing to laboratories and clinics in the United States and Europe, the next five years promise advances in classification, prognosis, drug resistance, and treatment duration that could reshape the outlook for every hairy cell leukemia patient, particularly those with variant disease or relapse who have waited longest for options equal to those enjoyed by the majority.

Subject of Research: New research funding for hairy cell leukemia diagnosis, prognosis, and therapy development

Article Title: Nearly $7 million in new funding accelerates hairy cell leukemia research

Article References: Nearly $7 million in new funding accelerates hairy cell leukemia research. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: hairy cell leukemia, Blood Cancer United, Hairy Cell Leukemia Foundation, HCL2030, blood cancer research grants, variant hairy cell leukemia, vemurafenib, drug resistance, relapse, rare disease funding, combination therapy, all-oral treatment

Hairy cell leukemia is an uncommon malignancy of hematopoietic stem cells, named for the fine, hair-like projections that cover the surface of the malignant cells. It predominantly affects men and is driven in nearly all cases by a single acquired mutation, BRAF V600E, which was identified more than a decade ago and has since become both a diagnostic marker and a therapeutic target. The disease has a remarkable treatment history: described first in 1923, it was initially managed with splenectomy, then advanced through interferon and the purine analog pentostatin before cladribine, a nucleoside analog that is toxic to lymphocytes, became the backbone of therapy. More recently, combinations of cladribine with the monoclonal antibody rituximab have pushed remission rates even higher, and BRAF inhibitors such as vemurafenib have shown excellent results in refractory cases. Yet for all these advances, the standard cladribine schedule, a continuous infusion given on five to seven consecutive days, has remained essentially unchanged for two decades.

That constancy has persisted despite a persistent problem: toxicity. Cladribine profoundly depletes normal white blood cells, particularly neutrophils, leaving patients vulnerable to serious bacterial infections. Many require hospitalization, intravenous antibiotics, growth factor support, and blood product transfusions during the weeks following treatment. The concern became acute roughly fifteen years ago when deaths occurred among patients receiving continuous cladribine infusions. This prompted a handful of investigators to ask whether the same drug, delivered as one weekly outpatient infusion instead of daily doses, might achieve comparable disease control with far less collateral damage. The idea has biological logic: cladribine is a long-acting drug that accumulates in lymphocytes, and stretching its delivery across weeks may moderate the depth and duration of immunosuppression without compromising the lethal effect on malignant cells. Prior studies comparing the two schedules, including two prospective randomized trials from European groups, produced mixed results, with some finding no significant difference in efficacy and others reporting fewer neutropenic and infectious complications with weekly dosing.

The new study, led by Jacqueline A. Turner and colleagues including William A. Robinson, adds substantially to this literature by combining treatment response data with long-term survival analysis and modern molecular monitoring. The researchers identified 36 treatment-naïve patients with hairy cell leukemia treated at their institution since 2002. Eighteen received intermittent cladribine, meaning one infusion per week for 5 to 7 weeks, while 18 received the standard continuous schedule of daily outpatient infusions over 5 to 7 days. The groups were broadly similar at baseline: 83.3 percent of patients in each group were male, and initial white blood cell counts, hemoglobin concentrations, and platelet counts were statistically indistinguishable. The median age at diagnosis differed notably, at 58 years in the weekly-dosing group versus 45 years in the continuous group, a disparity the authors acknowledge may reflect shifting referral patterns over the two-decade study window.

The efficacy results favored weekly dosing on every clinically meaningful measure tested. Beyond the difference in complete remission rates, 94.4 percent versus 61.1 percent, no patient in the weekly group experienced progressive disease, while 38.9 percent of the continuous-infusion group did. Kaplan-Meier analysis showed no difference in overall survival between the groups, a finding the authors attribute to the effectiveness of salvage therapies at relapse, but progression-free survival differed profoundly, with a p-value below 0.0001 by log-rank testing. Hospitalizations during treatment induction were less frequent with weekly dosing, affecting 4 of 18 patients compared with 6 of 18, and among three patients in the study who had relapsed after continuous cladribine and were later re-challenged with the weekly schedule, all achieved complete responses, with two remaining in remission for years and none requiring hospitalization during the weekly regimen, in contrast to hospitalizations and neutropenic fevers that had complicated their original continuous-infusion treatment.

Toxicity data painted a more nuanced picture. Neutropenia was nearly universal in both groups, affecting 88.9 percent of weekly-dosing patients and 92.9 percent of continuous-infusion patients with recorded data, and neutropenic fever occurred in roughly 43 to 44 percent of both groups. Antibiotic use was identical at 50 percent, and the proportion of patients requiring growth factor support or blood product transfusions was also comparable. This raises an important interpretive question, because the weekly group was far more likely to have received rituximab after cladribine, 72.2 percent versus 27.2 percent, a chemoimmunotherapy addition that has itself been shown to deepen remissions and extend survival. The authors are candid about this limitation, noting that the non-randomized design and the imbalance in rituximab exposure may have contributed to the observed differences and preclude definitive conclusions about which element of the regimen drives the benefit.

The study also offers a window into the future of disease monitoring in hairy cell leukemia. In a subset of more recently treated patients, the team used quantitative polymerase chain reaction on peripheral blood samples to track the frequency of the mutant BRAF V600E allele, essentially using the driver mutation itself as a measurable residual disease marker. At five years after treatment, all tested patients in both groups had undetectably low levels of the mutant allele, and the decline in mutant allele burden correlated closely with clinical remission. Because the assay requires only a blood draw, the authors argue it could serve as a less invasive alternative to the repeated bone marrow biopsies traditionally used to assess remission depth, and they recommend that serial BRAF mutant allele frequency testing be incorporated into routine care. The feasibility of monitoring relapse through a simple blood test is particularly attractive in a disease whose treatment is most effective when started early.

The rarity of hairy cell leukemia complicates the path forward. With only a few thousand new cases diagnosed annually in the United States, prospective randomized trials comparing the two schedules are difficult to mount and slow to accrue, which helps explain why the question has lingered for decades with only mixed and limited answers. The two previously conducted randomized trials, from the Polish Adult Leukemia Group and the Swiss Group for Clinical Cancer Research, found no significant efficacy differences, while earlier Italian work by Lauria and colleagues and by Zinzani and colleagues reported that weekly administration reduced infectious complications. The Colorado experience, with its extended follow-up and favorable progression-free survival signal, tilts the accumulated evidence somewhat further toward the weekly schedule, though the authors concede that confirmation in larger, prospective, ideally multi-institutional cohorts would be valuable and have committed to continuing to expand and update their own series.

For patients, the practical implications are appealing regardless of which component of the regimen proves decisive. A once-weekly outpatient infusion eliminates the logistical burden of consecutive daily hospital visits, and the reduced hospitalization rate translates into fewer exposures to drug-resistant hospital pathogens for an already immunocompromised population. Because most hairy cell leukemia patients are older and carry comorbidities, the authors emphasize that an ideal regimen must be both effective and low-risk across short- and long-term horizons, criteria they argue weekly cladribine followed by rituximab appears to meet. Their conclusion is measured but hopeful: the weekly schedule represents a feasible strategy supported by institutional experience, and while randomized validation would be ideal, the totality of the data, higher complete remission rates, superior progression-free survival, comparable overall survival and toxicity, and fewer hospitalizations, suggests a genuine clinical benefit that the field should not ignore.

The study arrives at a moment when the treatment of hairy cell leukemia is already undergoing a molecular renaissance, driven by the discovery that a single point mutation powers the disease and by the growing clinical repertoire of BRAF inhibitors and antibody combinations. Against that backdrop, the Colorado findings are a reminder that sometimes meaningful progress in oncology comes not from new molecules but from new ways of using old ones. Cladribine has been a mainstay of hairy cell leukemia therapy since the early 1990s, and if simply rearranging its administration calendar can keep more patients in durable remission with fewer trips to the hospital, the change would cost essentially nothing to implement. Whether weekly cladribine followed by rituximab formally becomes the new standard will depend on the larger studies the authors call for, but for a disease that has long been a treatment success story, this work proposes a way to make the story even better.